JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB258603

Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell lysate

Be the first to review this product! Submit a review

|

(0 Publication)

PRKACB KO cell lysate available now. KO validated by Western blot. Free of charge wild type control included. Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1.

View Alternative Names

KAPCB_HUMAN, PKA C-beta, PKACB, PRKACB, Protein kinase A catalytic subunit beta, Protein kinase cAMP dependent catalytic beta, cAMP-dependent protein kinase catalytic beta subunit isoform 4ab, cAMP-dependent protein kinase catalytic subunit beta

3 Images
Sanger Sequencing - Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell lysate (AB258603)
  • Sanger seq

Unknown

Sanger Sequencing - Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell lysate (AB258603)

Allele-2 : 1 bp insertion in exon 1

Sanger Sequencing - Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell lysate (AB258603)
  • Sanger seq

Unknown

Sanger Sequencing - Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell lysate (AB258603)

Allele-1 : 2 bp deletion in exon 1

Western blot - Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell lysate (AB258603)
  • WB

Lab

Western blot - Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell lysate (AB258603)

Lane 1 : Wild-type HeLa cell lysate 20 μg
Lane 2 : PRKACB knockout HeLa cell lysate 20 μg
Lane 3 : Wild-type HAP1 cell lysate 20 μg
Lane 4 : PRKACB knockout HAP1 cell lysate 20 μg
False colour image of Western blot : Anti-PKA beta (catalytic subunit) antibody staining at 1/500 dilution, shown in green; Mouse anti-Alpha Tubulin [DM1A] (ab7291) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab187515 was shown to bind specifically to PKA beta (catalytic subunit). A band was observed at 41 kDa in wild-type HeLa cell lysates with no signal observed at this size in PRKACB knockout cell line ab264673 (knockout cell lysate ab258603). To generate this image, wild-type and PRKACB knockout HeLa cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged.Secondary antibodies used were Goat anti-Rabbit IgG H&L (IRDye® 800CW) preabsorbed (ab216773) and Goat anti-Mouse IgG H&L (IRDye® 680RD) preabsorbed (ab216776) at 1/20000 dilution. 41 kDa observed band.

All lanes:

Western blot - Anti-PKA beta (catalytic subunit) antibody (<a href='/en-us/products/primary-antibodies/pka-beta-catalytic-subunit-antibody-ab187515'>ab187515</a>) at 1/500 dilution

Lane 1:

Wild-type HeLa cell lysate at 20 µg

Lane 2:

Western blot - Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell lysate (ab258603) at 20 µg

Lane 3:

Wild-type HAP1 cell lysate at 20 µg

Lane 4:

PRKACB knockout HAP1 cell lysate at 20 µg

Predicted band size: 41 kDa

Observed band size: 41 kDa

false

Key facts

Cell type

HeLa

Species or organism

Human

Tissue

Cervix

Knockout validation

Sanger Sequencing,Western blot

Mutation description

Knockout achieved by using CRISPR/Cas9, 1 bp insertion in exon 1 and 2 bp deletion in exon 1.

Disease

Adenocarcinoma

style
left-column

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "Sanger seq": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }
style
left-column

Product details

Knockout cell lysate achieved by CRISPR/Cas9.

REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.

Lysate preparation: Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10). This means that the protein of interest is denatured. If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.

User storage instructions: Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.

This product is subject to limited use licenses from The Broad Institute, ERS Genomics Limited and Sigma-Aldrich Co. LLC, and is developed with patented technology. For full details of the licenses and patents please refer to our limited use license and patent pages.

style
left-column

What's included?

{ "values": { "1Kit": { "sellingSize": "1 Kit", "publicAssetCode":"ab258603-1Kit", "assetComponentDetails": [ { "size":"1 x 100 µg", "name":"Human PRKACB knockout HeLa cell lysate", "number":"AB258603-CMP02", "productcode":"" }, { "size":"1 x 100 µg", "name":"Human wild-type HeLa cell lysate", "number":"AB258603-CMP01", "productcode":"" } ] } } }
style
left-column

Properties and storage information

Gene name
PRKACB
Gene editing type
Knockout
Gene editing method
CRISPR technology
Knockout validation
Sanger Sequencing, Western blot
Shipped at conditions
Ambient - Can Ship with Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
style
left-column

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

The PKA beta (catalytic subunit) also known as PRKACB or Protein Kinase A catalytic subunit beta plays a pivotal role in cellular signaling mechanisms. Mechanically it catalyzes the transfer of a phosphate group from ATP to a serine or threonine residue in target proteins impacting various cellular processes. This catalytic subunit has a molecular weight of approximately 40 kDa. It expresses widely in many tissues including the brain heart and skeletal muscle where it contributes to regulating metabolic and transcriptional activities.
Biological function summary

The PKA beta catalytic subunit functions in a larger context as part of the Protein Kinase A (PKA) complex which is a central player in the cyclic AMP (cAMP) signaling pathway. This complex acts as an effector of cAMP translating extracellular signals into intracellular actions by phosphorylating a wide range of target proteins. As a part of this complex it modulates activities related to glucose metabolism cell proliferation and gene expression reflecting its involvement in many cellular processes.

Pathways

PKA beta is integrally involved in the cAMP signaling and insulin signaling pathways. In the cAMP pathway it activates by binding to cAMP leading to dissociation from regulatory subunits and subsequent activation of substrate proteins. In the insulin signaling pathway it interacts with proteins like PI3K and Akt playing an important role in regulating glucose homeostasis and lipid metabolism. These pathways illustrate the PKA beta's importance in maintaining cellular and systemic metabolic balance.

The dysfunction of PKA beta is associated with conditions such as cardiac hypertrophy and certain types of cancer. Elevations or disruptions in PKA beta activity can lead to alterations in cell growth and metabolic regulation. PKA beta's relationship with proteins like CREB and Bcl-2 through these disorders has been observed where aberrant phosphorylation mediated by PKA can drive pathological cell survival proliferation and growth linking malfunction directly to disease progression.
style
left-column

Quality control

STR analysis

CSF1PO, D13S317, D7S820, D5S818, TH01, D16S539, TPOX

style
left-column

Cell culture

Biosafety level

EU: 2 US: 2

Adherent/suspension

Adherent

Gender

Female

style
left-column

Product protocols

style
left-column
style
left-column
style
right-column

Complementary Products

Primary Antibodies

AB187515

Anti-PKA beta (catalytic subunit) antibody

Immunocytochemistry/ Immunofluorescence - Anti-PKA beta (catalytic subunit) antibody (AB187515)

  • 0
  • 0
Primary Antibodies

AB76238

Anti-cAMP Protein Kinase Catalytic subunit antibody [EP2102Y]

RabMAb|Recombinant|20ul selling size

Flow Cytometry (Intracellular) - Anti-cAMP Protein Kinase Catalytic subunit antibody [EP2102Y] (AB76238)

  • 0
  • 0
Cell Lines & Lysates

AB264673

Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell line

Advanced Validation

Sanger Sequencing - Human PRKACB (PKA beta catalytic subunit) knockout HeLa cell line (AB264673)

  • 0
  • 0
Primary Antibodies

AB108385

Anti-PRKACG antibody [EP2647Y]

RabMAb|Recombinant

Western blot - Anti-PRKACG antibody [EP2647Y] (AB108385)

  • 3
  • 1

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com